Partnering with Academia – Insights from Princeton’s Engage 2021 Conference

By Jill N. Link, Pharm.D.

As counsel to various university clients as well as those in industry (of many types!) I am frequently asked my opinion of how best to work with academia to conduct research, while also maximizing the future ability to commercialize resulting intellectual property (IP). This is a question with many nuanced answers. I am not seeking […]

Continue Reading →

Two New ex Parte Trademark Cancellation Proceedings

By Julie L. Spieker

On December 18, 2021, new regulations implementing the Trademark Modernization Act of 2020 (“the TMA”) will officially go into effect allowing individuals, businesses, and the USPTO to clear unused registered trademarks from the federal trademark register. New ex parte expungement and reexamination proceedings are said to provide a faster, more efficient, and less expensive alternative […]

Continue Reading →

Federal Circuit dismisses another appeal by Apple Inc.

By Joseph M. Hallman

On November 10, 2021, in Apple Inc. v. Qualcomm Incorporated (Apple v. Qualcomm), the United States Court of Appeals for the Federal Circuit (“Federal Circuit”) dismissed Apple Inc.’s (“Apple”) consolidated appeal from four decisions made by the Patent Trial and Appeal Board (“PTAB”). The PTAB held that claims of patents owned by Qualcomm Incorporated (“Qualcomm”) […]

Continue Reading →

When your own patent application counts as prior art: Beware the Continuation-In-Part

By Cassie J. Edgar

Often during patent prosecution new technologies, concepts and data grow out of an original filing. How can you protect those new innovations? The natural reaction is to file a child application off of the parent filing, in order to preserve the earlier priority date through a continuation or continuation-in-part (CIP) application. A continuation is limited […]

Continue Reading →

Congressman/Inventor Introduces Legislation to “Fix” U.S. Patent System

By Kirk M. Hartung

On November 4th, Kentucky Representative, Thomas Massie, who is the named inventor on two dozen patents, has introduced a bill to the House Judiciary Committee which, if passed, would significantly change U.S. patent laws. The bill seeks to nullify some provisions of the America Invents Act (AIA) passed in 2011, as well as reverse some […]

Continue Reading →

MVS Recognized Again By Best Lawyers “Best Law Firm” Rankings as a Top Law Firm

By Richard Marsolais

McKee, Voorhees & Sease is proud to be recognized by U.S. News & World Report and Best Lawyers® for their “Best Law Firms” Tier 1 rankings in Des Moines for Copyright Law, Intellectual Property Litigation, Patent Litigation, Patent Law, and Trademark Law. Firms included in the 2022 “Best Law Firms” list are recognized for professional […]

Continue Reading →


By Charles P. Romano, Ph.D.

In the immediate wake of the Belcher v. Hospira case where the patent holder made contradictory statements to the USPTO and the FDA regarding prior art, Senators Leahy and Tillis called for “the creation of a smooth, predictable, and regular channel of information from other federal agencies to the Patent Office” in a letter to […]

Continue Reading →

The Great Dichotomy: Patent Protection vs. Regulatory Approval

By Cassie J. Edgar

As a scientist in discovery mode, the primary focus is often on points of novelty and seeking patent protection for the invention.  The supporting data in the patent application serves as proof that this is a unique innovation, has never been seen before, and overcomes key challenges.  However, when the product is regulated, converse arguments […]

Continue Reading →

Biden Names Winston & Strawn’s Vidal For USPTO Director

By Heidi Sease Nebel

President Biden announced today that he is nominating Kathi Vidal of Winston & Strawn as the new U.S. Patent and Trademark Office (USPTO) Director.  Vidal is a patent litigator and managing partner of the Silicon Valley office of Winston & Strawn, where she has been since 2017.  Prior to that, she was with Fish & […]

Continue Reading →

Psilocybin Patents Demonstrate Growth in the Psychedelics Market

By Sarah M.D. Luth

Public and medical interest in the use of psychedelics has steadily been expanding since the 1990s. Psilocybin is one of the most well-known psychedelic compounds. Psilocybin, also known as “magic mushrooms” is a compound produced by several species of fungi, and which has both psychoactive and hallucinogenic properties. Although psilocybin is still considered a Schedule […]

Continue Reading →

Stay in Touch

Receive the latest news and updates from us and our attorneys.

Sign Up